Editor's note: The person posting comments as "RJ Kirk" in Tuesday's BIO CEO Live Blog is not the chairman of Clinical Data.
NEW YORK (TheStreet) -- Small- and midsized biotech companies get a second day in the investor spotlight this week at the 13th annual BIO CEO & Investor Conference.
I'll be continuing my live-blogging from the BIO CEO conference today, presenting news updates and analysis live from the presentation rooms and breakout (Q&A) sessions.Biotech companies on my coverage list Tuesday include: Spherix (SPEX), SuperGen (SUPG), Clinical Data (CLDA), Cel-Sci (CVM), Aastrom Biosciences (ASTM), AVI BioPharma (AVII) and Neoprobe (NEOP). >>BIO CEO Conference Blog, Day 1 I'll also be reporting on presentations from StemCells (STEM), YM BioSciences (YMI), Ziopharm Oncology (ZIOP), Cell Therapeutics (CTIC), Icagen (ICGN) and Telik (TELK). The BIO CEO conference is sponsored by BIO, the biotech industry-lobbying group based in Washington, D.C., and typically invites small- and mid-cap biotech companies to present to an audience of institutional investors. Smaller biotech companies, in particular, lack extensive research coverage from investment banks, so this conference is a good way for these companies to get their stories in front of investors. This BIO CEO confab live blog will be similar to the real-time coverage I provided in January of the J.P. Morgan Healthcare Conference. Expect breaks in between my postings today because I'll be moving around the conference and waiting for companies to present throughout the day. I'll do my best to give you continuous coverage, but understand that I'm somewhat at the mercy of the AT&T network and my ability to type into my iPhone while weaving through crowds and listening to biotech executives speak. Your best bet is to check back into the live blog several times throughout the day. Like my previous live blogs, I want to keep today's coverage interactive, so feel free to ping me with comments and questions. I will publish and respond to as many of your comments and questions as I can. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV